Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis

The efficacy of Bruton tyrosine kinase inhibitors (BTKi) remains suboptimal in chronic lymphocytic leukemia (CLL) treatment. A systematic review and meta-analysis were conducted to compare the outcomes of combining anti-CD20 monoclonal antibodies (mAb) with BTKi therapy versus BTKi monotherapy for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Thuy, Nhu, Nguyen Thanh, Tran, Van Khoi, Viet-Nhi, Nguyen-Kieu, Ho, Xuan Dung, Jhan, Ming-Kai, Chen, Ya-Ping, Lin, Chiou-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276018/
https://www.ncbi.nlm.nih.gov/pubmed/37328530
http://dx.doi.org/10.1038/s41598-023-36279-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276018/
https://www.ncbi.nlm.nih.gov/pubmed/37328530
http://dx.doi.org/10.1038/s41598-023-36279-x

Ejemplares similares